Price Caps In Regeneron’s COVID Monoclonal Deal With HHS: Not A Precedent, But Enough For Bernie

 
• By Derrick Gingery
COVID-19 monoclonal antibody
Regeneron is developing a new monoclonal antibody for prevention of COVID-19 with its BARDA contract. • Source: Shutterstock

More from R&D

More from Pink Sheet